HBV associated liver inflammation
Conditions
Interventions
Hepatitis quiescent group:no
Hepatitis activity group:no
Hepatic failure group:no
Healthy control group:no
Flow cytometry Immunoclearance period group:no
Flow cytometry Chronic plus acute liver failure group:no
Flow cytometry Hepatitis B reactivity period group:no
Flow cytometry Chronic liver failure group:no
Sponsors
The First Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1, hepatitis static phase group: immune tolerance phase patients (hepatitis B Da-Sanyang, liver function is completely normal), immune control phase patients (hepatitis B minor Sanyang, liver function is normal); 1. Hepatitis quiescent stage group: patients in immune tolerance stage (HBsAg +,HBeAg +,HBcAb +, liver function is completely normal), patients in immune control stage (HBsAg +,HBeAb +,HBcAb +, liver function is normal); 2. Hepatitis activity group: patients in the immune clearance stage (HBsAg +,HBeAg +,HBcAb +, abnormal liver function), patients in the hepatitis B reactivity stage (HBsAg +,HBeAb +,HBcAb +, recurrent abnormal liver function, liver fibrosis); 3. Liver failure group: patients with chronic plus acute liver failure and chronic liver failure (in line with the diagnostic criteria for hepatitis B liver failure in 2018 edition); 2, hepatitis activity group: immune clearance period patients (hepatitis B Dasan Yang, liver function abnormalities), hepatitis B reactivity period patients (hepatitis B minor Sanyang, liver function repeated abnormalities, liver fibrosis); 3. Liver failure group: patients with chronic plus acute liver failure and chronic liver failure (in line with the diagnostic criteria for hepatitis B liver failure in 2018 edition); 4. Healthy control group: healthy adults without hepatitis B and other liver diseases; 5, prothrombin time is less than 20 seconds, platelet greater than 80*10^9/L.
Exclusion criteria
Exclusion criteria: 1. Complicated with serious organic diseases; 2, combined with autoimmune related diseases; 3. Co-infection; 4. Abnormal liver function due to other causes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of cell subpopulations;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;total bilirubin;prothrombin time; | — |
Secondary
| Measure | Time frame |
|---|---|
| albumin;thrombocyte;creatinine; | — |
Countries
China
Contacts
Public ContactQin Mao
The First Affiliated Hospital of the Army Medical University
Outcome results
None listed